Shin Nippon's migraine treatment spinoff, Satsuma Pharmaceuticals, floated above its range to raise $82.5m in an offering that follows $86m of funding.

The SoftBank-backed biological analysis technology provider priced its shares above its range and will likely close the offering at $449m.

Livongo priced its shares above their range to raise more than $355m, providing exits to Merck GHI, M12, Humana, Zaffre Investments and Echo Health Ventures.

Health Catalyst, which counts several care providers as investors, has raised $182m in its initial public offering, with its share price shooting up more than 50% on the first day of trading.

Phreesia has raised more than $167m in proceeds after pricing shares above its range at $18, providing exits to BlueCross BlueShield, Ascension Health and Echo Health Ventures.

Mirum Pharmaceuticals has raised $75m in its initial public offering that had an initial target of $86.3m and provided exits to Novo and Shire.

GlaxoSmithKline, Sanofi and 6 Dimensions Capital have all secured exits as the rare disease treatment developer raised $72m in its initial public offering.

Tencent-backed Douyu has successfully listed on Nasdaq after completing a $775m initial public offering that came after economic tensions forced a delay earlier this year.

IndiaMart, backed by Intel Capital and Brand Equity Treaty, has listed on the National Stock Exchange after raising $69m in its initial public offering.

PureTech Health spinoff Karuna Therapeutics has upscaled its IPO to nearly $103m, after its shares rose by more than 50% in its first days of trading.